Latest News

Searle launches Rhulef™ [Leflunomide]

Rhulef™ is FDA approved latest DMARD treatment for Rheumatoid Arthritis which causes significant reduction in pain and reduces morning stiffness in joints. Rhulef™ is available in alu-alu blister packing with convenient once daily oral dosage.


Searle launches a novel probiotic, Ecotec™

Ecotec™ is a multistrain and multispecies probiotic which eliminates the ecological damage of intestinal flora caused by several diseases including antibiotic associated diarrhea, traveler's diarrhea, diarrhea for the non-specific origin and it is also recommended in IBS and IBD.


Searle introduces Alar™ [Artemether + Lumefantrine]

Alar is a first line anti-malarial combination therapy recommended by WHO, and comprises Artemether + Lumefantrine combination. It is a safe and effect therapy available in a recommended six dose regime of 20 mg (Artemether) and 40 mg (Lumefantrine) combination at an affordable price.


Inauguration of new Sterile Area, R&D Scale-up Facility at Karachi

Searle inaugurated a new, high-tech state of the art Sterile Area (Liquid Injectable Ampoule), R&D scale-up facility for oral solid dosage and Special Health Care Products Manufacturing Unit at Karachi.

The facility was inaugurated by CEO Searle Pakistan Ltd and the ceremony was attended by Deputy Managing Director Mr. Syed Nadeem Ahmed and all the directors of the company.

The CEO in his remarks said "it is a historic moment for all of us and is an evidence of our constant efforts for a successful Pharmaceutical Business. I extend my gratitude to each member of Searle Pakistan and appreciate the utmost efforts of all in establishing the name of the company as symbol of quality and trust."


Inauguration of Second Pharmaceutical Manufacturing Facility in Lahore

Searle inaugurated its new high-tech manufacturing plant in the city of Lahore, which is the second manufacturing unit after Karachi which was established back in 1965.

To attend the inaugural ceremony, a large number of the business community and the pharmaceutical sector of Lahore were present among the audience along with the representation of every division of Searle Pakistan and the prospect employees of the new plant. Mr. Rashid Abdulla, CEO and Managing Director, Searle Pakistan Limited was the Chief Guest at the occasion.

The CEO Inaugurates the Searle Lahore Facility

Syed Nadeem Ahmed, Deputy Managing Director of SPL, introduced the newly developed state-of-the-art manufacturing unit and said that Searle Pakistan is one of the fastest growing pharmaceutical companies of the country whose vision is to lead in improving the quality of human life by introducing new research products.

After the introductory speech, SPL's CEO, Mr. Rashid Abdulla along with other guests were invited for the ceremonial inauguration and ribbon cutting. Subsequently the CEO with other guests formally visited each and every production unit of the plant while Mr. Syed Nadeem Ahmed briefly introduced the different sections while proclaiming that they have kept all international guidelines and GMP rules in the development of the plant.


New Refreshing Look of Selanz SR™

With the objective to fulfilling the commitment of quality products with patient friendly price, Searle has re-launched Selanz SR™ in August 2008 with a new package. This has not only given it a refreshed new look but also improved its reliability as the product is now presented in double aluminum foil blisters.


Searle Introduces Launch of Maxlox™ [Moxifloxacin]

Searle proudly launched another significant molecule, Moxifloxacin by the brand name of Maxlox™. Maxlox™ is a broad spectrum antibiotic and considered to be an upcoming drug of choice for respiratory tract infections. Maxlox™ has a novel chemical structure which enhances the gram +ve coverage and minimizes development of resistance. It also has a favorable pharmacodynamic and pharmacokinetic profile.

Maxlox™ is available in tablet of 400 mg in a commercial pack of 5's with alu-alu blister. Maxlox™ is freely available across the country at an affordable price.


Searle Launches Glitos Plus™ [Pioglitazone + Metformin]

Searle Pakistan proudly introduces Glitos Plus™, a combination of pioglitazone and Metformin, effective for hyperglycemia in elderly and obese. Glitos Plus™ controls multiple complications such as hyperlipidemia and is efficient in glucose control when compared with other combinations.


Searle introduces Vaptor™ [Rosuvastatin] for the treatment of Hypercholesterolemia and Mixed Dyslipidemia

Searle Pakistan Limited is pleased to introduce Vaptor™ (Rosuvastatin) for the management of Hypercholesterolemia and Mixed Dyslipidemia. Vaptor™ (Rosuvastatin) is also found to regresses the coronary atherosclerosis and approved by FDA in this indication.